RET split FISH on the tissue arrays identified 22 fusion-positive tumors in 1,528 lung cancers , from which a multiplex RT-PCR system that captures all possible KIF5B-RET fusions detected 12 ...

SAN DIEGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced ...

SAN DIEGO, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drug ...

New Phase 1b clinical data on RXDX-105 presented this week at the ESMO 2017 Congress in Madrid, Spain demonstrated clinical activity in RET fusions and compelling response rate in an ultra-rare ...

Genome research – Fusion of KIF5B and RET transforming gene in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing Recent strides have been made to identify gene mutation ...

RXDX-105 achieved promising results in non-KIF5B RET fusions with 6/8 patients responding for an ORR of 75%, but came up short in KIF5B fusions with 0/14 patients responding to treatment.

Gene abnormalities discovered in a subpopulation of lung and colorectal tumors could identify patients with a heightened response to highly specific drugs used for other cancers, according to ...

Foundation Medicine, Inc. and Dana-Farber Cancer Institute have announced the Nature Medicine publication of results from their collaborative next-generation sequencing (NGS) study to assay ...

Available as 100 mg capsules, pralsetinib is a RET-receptor tyrosine kinase inhibitor, targeting oncogenic RET fusion proteins (KIF5B-RET and CCDC6-RET).

--Turning Point Therapeutics, Inc., a precision oncology company developing novel drugs to address treatment resistance, today announced initiation of a Phase 1/ 2 clinical study of its drug ...